Company profile for Genome & Company

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Genome & Company which is researching and developing dietary supplements, cosmeceuticals, and new drugs utilizing microbiome, pursues people’s happy life. We have been studying microbes and probiotics which can be applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies with the vision of becoming the Asian Flagship Company of the Human Microbiome Industry and the objective of market drive...
Genome & Company which is researching and developing dietary supplements, cosmeceuticals, and new drugs utilizing microbiome, pursues people’s happy life. We have been studying microbes and probiotics which can be applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies with the vision of becoming the Asian Flagship Company of the Human Microbiome Industry and the objective of market driven product development by 2018. We seek to identify what causes diseases, integrating the functional mechanism using a simulator of the human colon microbial ecosystem and multi-omics profiling.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
Silicon Park B-8F 35, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi...
Telephone
Telephone
+82-31-628-0150
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240603093689/en

BUSINESSWIRE
03 Jun 2024

https://www.fiercebiotech.com/biotech/genome-company-posts-data-phase-2-microbiome-cancer-trial-plans-more-studies

FIERCE BIOTECH
24 Jan 2024

https://www.prnewswire.com/news-releases/positive-results-from-interim-analysis-of-gen-001-plus-avelumab-bavencio-phase-ii-trial-301829278.html

PR NEWSWIRE
19 May 2023

https://www.contractpharma.com/contents/view_breaking-news/2021-09-23/cdmo-list-labs-partners-with-genome-company/?widget=listSection

CONTRACTPHARMA
23 Sep 2021
Rome bags $77M to strike gold in the backwaters of the genome
Rome bags $77M to strike gold in the backwaters of the genome

14 Sep 2021

// Nick Paul Taylor FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/kapeller-s-rome-bags-77m-to-strike-gold-backwaters-genome

Nick Paul Taylor FIERCEBIOTECH
14 Sep 2021
Genome of South Korea purchases CDMO List Labs for $27M
Genome of South Korea purchases CDMO List Labs for $27M

09 Sep 2021

// Kevin Dunleavy FIERCEPHARMA

https://www.fiercepharma.com/manufacturing/microbiome-developer-genome-south-korea-acquires-cdmo-capability-27m-purchase-list

Kevin Dunleavy FIERCEPHARMA
09 Sep 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty